ALT vs KLRA
ALT: A clinical-stage biopharmaceutical company developing dual-agonist peptide therapeutics targeting the massive obesity and metabolic disease markets. KLRA: A clinical-stage biotech developing a diversified pipeline of GLP-1-based obesity management drugs, led by a dual GLP-1/GIP agonist injectable designed to deliver superior weight loss potential.
Side-by-side fundamentals
| Metric | ALT | KLRA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $2.96 | $17.48 | |
| Market cap as of 2026-07-31 | $576M | $2.3B | |
| Net margin as of 2026-07-31 | -214861.0% | n/a | |
| Gross margin as of 2026-07-31 | +100.5% | n/a | |
| Operating margin as of 2026-07-31 | -230461.0% | n/a | |
| ROE as of 2026-07-31 | -42.6% | -23.4% | KLRA higher |
| ROA as of 2026-07-31 | -35.6% | -21.5% | KLRA higher |
| Debt / equity as of 2026-07-31 | 0.12 | 0.00 | KLRA lower |
| Revenue growth (YoY) as of 2026-07-31 | +80.0% | n/a | |
| Beta as of 2026-07-31 | 0.14 | 1.71 | |
| 1-year return as of 2026-07-27 close | -27.5% | n/a |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.